It is intriguing that targeting mPFC SST-INs reverses schizophrenia-like deficits in light of abundant evidence of PV-IN dysfunction in schizophrenia (Behrens et al., 2007; Gonzalez-Burgos et al., 2015; Homayoun and Moghaddam, 2007; Lodge et al., 2009; Mukherjee et al., 2019). The gene discussed is SST; the disease is schizophrenia.